Other studies have maintained that ER-/PR+ breast cancer is too rare (0 to 0.1% frequency) to represent a true disease subtype and that as IHC-based methods for ER/PR assessment improve, the ER-/PR+ classification will become even rarer [2,17,18]. The gene discussed is ESR1; the disease is breast carcinoma.